Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01166139 · ClinicalTrials.gov registry record · Phase 2
Nilotinib in the Treatment of Systemic Sclerosis
A Phase 2 study, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01166139 is a Phase 2 study that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 10 participants.
The verdict
NCT01166139, a Phase 2 study, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
A phase IIa open-label single center pilot study to assess the safety and efficacy of Nilotinib in patients with Scleroderma.
Interventions
- DRUG Nilotinib (Tasigna)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01166139
The ClinicalTrials.gov registry entry for NCT01166139 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nilotinib (Tasigna) is the first listed.
NCT01166139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01166139 about?
NCT01166139 is a clinical study titled "Nilotinib in the Treatment of Systemic Sclerosis". A phase IIa open-label single center pilot study to assess the safety and efficacy of Nilotinib in patients with Scleroderma.
What is the current status of trial NCT01166139?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2010-07. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01166139?
The interventions under investigation include: Nilotinib (Tasigna) (DRUG).
Who is sponsoring clinical trial NCT01166139?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.